Physician profile
Scott Lightfoot
NPI 1750337192
$61,153.93
in general payments reported to CMS, 2019-2025
73 companies · $4,443 in 2025
The $4,443 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,309 · 2022: $15K · 2023: $12K · 2024: $23K · 2025: $4,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $14K · Travel and Lodging: $7,296 · Education: $580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,535.00 |
| Food and Beverage | $14,243.09 |
| Travel and Lodging | $7,295.76 |
| Education | $579.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $21,451.60 | 2021-2025 | Tagrisso, Imfinzi, Lynparza |
| Alexion Pharmaceuticals, INC. | $18,765.30 | 2022-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $1,464.28 | 2021-2025 | |
| Genzyme Corporation | $1,365.05 | 2021-2025 | |
| Pfizer INC. | $1,338.32 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $1,257.28 | 2021-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $1,032.53 | 2021-2025 | Opdivo, Opdualag, Reblozyl |
| Abbvie INC. | $928.32 | 2021-2025 | |
| Zimvie INC. | $919.04 | 2022-2024 | |
| Gilead Sciences, INC. | $906.74 | 2021-2025 | Trodelvy |
| Seagen INC. | $866.41 | 2021-2023 | Tukysa, Padcev, Adcetris |
| Astellas Pharma US INC | $817.71 | 2021-2025 | Padcev, Vyloy, Xtandi |
| Amgen INC. | $767.43 | 2021-2023 | Kyprolis, Lumakras, Vectibix |
| Celgene Corporation | $741.05 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Genentech USA, INC. | $654.18 | 2021-2025 | Alecensa, Tecentriq, Polivy |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $558.56 | 2021-2025 | Darzalex, Tecvayli, Carvykti |
| Daiichi Sankyo INC. | $530.04 | 2021-2025 | Enhertu, Injectafer |
| Stemline Therapeutics INC. | $406.30 | 2023-2025 | Orserdu |
| Lilly USA, LLC | $390.75 | 2021-2025 | Verzenio, Jaypirca |
| Glaxosmithkline, LLC. | $356.66 | 2021-2025 | Zejula, Jemperli, Shingrix |
| Pharmacyclics LLC, An Abbvie Company | $344.74 | 2021-2023 | Imbruvica, Epkinly |
| Puma Biotechnology, INC. | $341.96 | 2021-2025 | |
| Incyte Corporation | $285.16 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Sanofi-Aventis U.S. LLC | $284.97 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $240.42 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $237.80 | 2021-2025 | |
| Emd Serono, INC. | $219.63 | 2021-2025 | Bavencio, Tepmetko |
| Takeda Pharmaceuticals U.S.A., INC. | $205.53 | 2021-2025 | Iclusig, Fruzaqla, Alunbrig |
| Genmab U.S., INC. | $203.55 | 2023-2025 | Epkinly, Tivdak |
| Rigel Pharmaceuticals, INC. | $199.50 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Sumitomo Pharma America, INC. | $190.08 | 2024 | Orgovyx |
| Springworks Therapeutics, INC. | $186.47 | 2024-2025 | Ogsiveo |
| Blueprint Medicines Corporation | $184.76 | 2022-2025 | Ayvakit |
| Tersera Therapeutics LLC | $166.13 | 2022-2025 | Zoladex |
| Jazz Pharmaceuticals INC. | $158.62 | 2021-2024 | |
| Exelixis INC. | $148.96 | 2021-2025 | Cabometyx |
| Kite Pharma, INC. | $135.21 | 2022-2025 | Yescarta |
| Ipsen Biopharmaceuticals, INC | $124.88 | 2021-2025 | Onivyde, Tazverik |
| Geistlich Pharma, North America, INC. | $122.72 | 2021 | |
| Array Biopharma INC | $120.98 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Eisai INC. | $113.19 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $110.10 | 2022-2024 | Xpovio |
| Adaptive Biotechnologies Corporation | $89.12 | 2022-2024 | Clonoseq |
| Geron Corporation | $86.39 | 2025 | Rytelo |
| Regeneron Healthcare Solutions, INC. | $82.65 | 2022-2025 | Libtayo |
| Mirati Therapeutics, INC. | $81.42 | 2023-2024 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.78 | 2021-2024 | Gilotrif |
| Taiho Oncology, INC. | $72.50 | 2021-2025 | |
| Adc Therapeutics America, INC. | $69.17 | 2022-2025 | |
| Beigene USA, INC. | $59.24 | 2023-2024 | Brukinsa |
| Deciphera Pharmaceuticals INC. | $58.75 | 2023-2025 | Qinlock, Romvimza |
| Coherus Oncology, INC. | $55.74 | 2021-2024 | |
| Kyowa Kirin, INC. | $46.86 | 2023-2025 | Poteligeo |
| Azurity Pharmaceuticals, INC. | $45.04 | 2025 | Danziten |
| Servier Pharmaceuticals LLC | $44.71 | 2024-2025 | |
| Morphosys, US INC. | $39.51 | 2021-2022 | |
| Pharmaessentia USA Corporation | $37.89 | 2025 | Besremi |
| Amag Pharmaceuticals, INC. | $36.00 | 2021 | |
| Sobi, INC | $35.43 | 2022 | |
| G1 Therapeutics, INC. | $34.92 | 2022 | |
| Myovant Sciences INC. | $30.79 | 2021-2022 | |
| Cti Biopharma Corp. | $28.19 | 2023 | Vonjo |
| Beone Medicines USA, INC. | $27.22 | 2025 | Tevimbra |
| Agios Pharmaceuticals, INC. | $26.66 | 2025 | Pyrukynd |
| Clovis Oncology, INC. | $21.21 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $19.49 | 2022 | |
| Immunocore Limited | $18.25 | 2025 | Kimmtrak |
| Progenics Pharmaceuticals, INC. | $17.94 | 2024 | |
| Nobel Biocare USA | $15.20 | 2023 | Nobelactive |
| Ormco Corporation | $15.20 | 2023 | Spark |
| Caris Mpi, INC. | $14.25 | 2025 | Mi Cancer Seek |
| Sun Pharmaceutical Industries INC. | $12.34 | 2022 | |
| Dova Pharmaceuticals | $12.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Lightfoot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.